Amicus Therapeutics
Amicus Therapeutics is a global biopharmaceutical company headquartered in Princeton, NJ, specializing in treatments for rare diseases such as Fabry, Pompe, and Batten Diseases. The company offers products like Galafold® and Pombiliti™ + Opfolda™, and is publicly traded on NASDAQ under the ticker symbol FOLD.
Global Presence of Amicus Therapeutics
Amicus Therapeutics has established a global presence with offices in Australia, Canada, France, Germany, Italy, Japan, Netherlands, Spain, Switzerland, and the United Kingdom. The company's international reach enables it to provide treatments and support for rare diseases to a broad patient population around the world. This extensive network underscores Amicus Therapeutics' commitment to addressing the needs of patients on a global scale.
Treatments for Rare Diseases
Amicus Therapeutics specializes in developing therapies for rare diseases such as Fabry Disease, Pompe Disease, and Batten Disease. The company's focus on these conditions demonstrates its dedication to addressing unmet medical needs and improving the lives of patients with rare genetic disorders. Through its innovative research and development efforts, Amicus is at the forefront of creating solutions for some of the most challenging medical conditions.
Amicus Therapeutics Products
Amicus Therapeutics offers several products designed to treat rare genetic diseases. These include Galafold® (migalastat) and the combination therapy Pombiliti™ + Opfolda™ (cipaglucosidase alfa-atga) (miglustat). These therapies provide new treatment options for patients affected by Fabry Disease and Pompe Disease, respectively. Through these offerings, the company aims to enhance patient outcomes and quality of life.
Patient Support Program AMICUS ASSIST®
The AMICUS ASSIST® program by Amicus Therapeutics provides comprehensive patient support, ensuring individuals have access to the necessary resources and assistance throughout their treatment journey. This initiative is part of the company's broader commitment to patient care, offering personalized support services that help patients navigate their healthcare needs and improve their treatment experiences.
Research and Development at Amicus Therapeutics
Amicus Therapeutics has a dedicated Global Research Center, which plays a crucial role in the company’s efforts to develop innovative treatments for rare diseases. The center is part of the company's broader strategy to leverage cutting-edge technology platforms and advance its comprehensive pipeline of programs. This commitment to research and development underpins Amicus’s mission to bring new and effective therapies to patients with genetic disorders.
Corporate Responsibility Initiatives
Amicus Therapeutics is committed to corporate responsibility, engaging in various initiatives across ethics and compliance, global medical affairs, and corporate giving. The company supports patient and professional nonprofit healthcare-related organizations through educational grants and charitable contributions. Additionally, Amicus publishes an annual Environmental, Social, and Governance (ESG) report, highlighting its efforts in sustainable and ethical business practices.
Stock and Market Information
Amicus Therapeutics is publicly traded on the NASDAQ Global Market under the ticker symbol FOLD. This listing provides investors with the opportunity to invest in a company focused on developing treatments for rare diseases. The company's regular events and presentations offer updates on financial results and corporate developments, ensuring transparency and continuous information flow to its shareholders and the broader market.